Vqe Active Space Drug Benchmark

---
name: vqe-active-space-drug-benchmark
description: Systematic benchmark methodology for active space selection in VQE-driven quantum drug discovery pipelines. Classifies molecule suitability for quantum computing using chemically grounded metrics, evaluates VQE across UCCSD and HEA ansatze with both simulation and QPU execution on drug-like molecules (lovastatin, oseltamivir, morphine).
version: 1.0.0
category: quantum-medical
activation_keywords: [VQE active space, quantum drug discovery, active space benchmark, UCCSD drug molecule, HEA ansatz drug, molecular suitability quantum, VQE pipeline benchmark, lovastatin quantum, oseltamivir quantum]
last_updated: 2026-06-17
source: arxiv:2512.18203
---

# VQE Active Space Selection Benchmark for Drug Discovery

## Source
**Paper**: "Benchmarking the Impact of Active Space Selection on the VQE Pipeline for Quantum Drug Discovery"
**arXiv**: 2512.18203 (December 2025)
**Authors**: Zhi Yin, Xiaoran Li, Zhupeng Han, Shengyu Zhang, Xin Li, Zhihong Zhang, Runqing Zhang, Anbang Wang, Xiaojin Zhang

## Problem Statement
Applying Variational Quantum Eigensolvers (VQE) to realistic drug-like molecules on NISQ hardware remains challenging. **Active space selection** is a key strategy to leverage current hardware effectively, yet remains under-benchmarked. This work introduces the first systematic benchmark for active space-driven VQE in quantum drug discovery.

## Methodology

### Molecule Suitability Classification
Heuristic criteria based on chemically grounded metrics to classify whether a molecule is suitable for quantum computing:

1. **Electronic Structure Complexity**: Number of correlated electrons, orbital degeneracy
2. **Active Space Size**: Feasible qubit count for NISQ hardware (typically 10-30 qubits)
3. **Chemical Significance**: Presence of pharmacophores, reactive centers, metal centers
4. **Classical Intractability**: Cases where classical methods (DFT, CCSD(T)) struggle

### Benchmark Molecules
- **Lovastatin**: Statin drug, complex ring system
- **Oseltamivir**: Antiviral (Tamiflu), amine-containing
- **Morphine**: Opioid analgesic, complex polycyclic structure

### VQE Evaluation Setup

**Ansätze Tested**:
- **UCCSD**: Unitary Coupled Cluster with Singles and Doubles (chemistry-accurate but deep circuits)
- **HEA**: Hardware-Efficient Ansatz (shallower, hardware-friendly but less chemically motivated)

**Execution Modes**:
- **Statevector Simulation**: Noiseless baseline
- **QPU Execution**: Real quantum hardware with noise

**Evaluation Metrics**:
- **Chemistry metrics**: Energy error vs FCI/CCSD(T) reference, dissociation curve accuracy
- **Architecture metrics**: Circuit depth, parameter count, gate count, hardware compatibility

### Active Space Selection Strategies
1. **Chemically Motivated**: Domain-expert selection based on molecular orbital analysis
2. **Automated Heuristic**: Algorithmic selection based on orbital energy gaps, occupation numbers
3. **Comparative Analysis**: Systematic comparison across active space sizes

## Implementation Steps

1. **Molecule Selection**: Choose drug-like molecules with known pharmacological relevance
2. **Classical Pre-computation**: Run HF/DFT to obtain molecular orbitals
3. **Active Space Selection**: Apply heuristic criteria to select active orbitals
4. **VQE Setup**: Configure UCCSD and HEA ansätze for each active space
5. **Execution**: Run on simulator and QPU
6. **Evaluation**: Compare energy accuracy, circuit complexity, hardware performance
7. **Benchmark Report**: Classify molecules by quantum readiness

## Key Insights

### UCCSD vs HEA Trade-offs
- **UCCSD**: Higher accuracy but deeper circuits, more prone to noise on real hardware
- **HEA**: Shallower circuits, better hardware performance but less chemical accuracy
- **Active space size** critically affects both: larger spaces need UCCSD for accuracy but may exceed hardware limits

### Hardware-Algorithm Co-Design
- Active space selection should consider **target hardware constraints** (qubit count, connectivity, coherence time)
- Different molecules require different active space strategies based on their electronic structure

## Pitfalls

### 1. Active Space Too Small
**Problem**: Missing important correlation effects, inaccurate energies.
**Solution**: Use chemical intuition + automated heuristics to ensure all relevant orbitals are included.

### 2. Active Space Too Large
**Problem**: Circuit depth exceeds NISQ capabilities, noise destroys results.
**Solution**: Benchmark molecule suitability before committing to VQE.

### 3. HEA Ansatz Chemical Accuracy
**Problem**: HEA may not capture correct chemical physics even with enough parameters.
**Solution**: Use UCCSD for accuracy-critical applications, HEA for hardware-feasibility studies.

### 4. Reference Method Selection
**Problem**: Need reliable classical reference (FCI, CCSD(T)) to evaluate VQE accuracy.
**Solution**: Use CCSD(T) for drug-sized molecules where FCI is intractable.

## Verification
- VQE energy should converge to classical reference as active space increases
- UCCSD should be more accurate than HEA on simulators
- HEA should be more robust on real QPU hardware
- Active space selection criteria should correctly predict molecule suitability for quantum computing

## Related Skills
- vqe-active-space-benchmarking
- quantum-drug-discovery
- quantum-chemistry
- dft-embedded-quantum-chemistry